When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Daratumumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Daratumumab/hyaluronidase

   It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]

3. Genmab’s Darzalex Gets FDA Approval For Blood ... - AOL

   www.aol.com/news/genmab-darzalex-gets-fda...

   Genmab A/S announced on Jan. 15 that its drug, Darzalex Faspro has been approved by the US Food and Drug Administration (FDA) for the treatment of light-chain (AL) amyloidosis in adult patients ...

4. AL amyloidosis - Wikipedia

   en.wikipedia.org/wiki/AL_amyloidosis

   Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. [1] The disease is caused when a person's antibody -producing cells do not function properly and produce abnormal protein fibers made of components of antibodies called light chains .

5. Daratumumab - Wikipedia

   en.wikipedia.org/wiki/Daratumumab

   Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]

6. Amgen (AMGN) Kyprolis Gets FDA Nod for Use With Darzalex Faspro

   www.aol.com/news/amgen-amgn-kyprolis-gets-fda...

   Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.

7. Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

   lite.aol.com/tech/story/0022/20250122/1001044358.htm

   COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024.